Cingulate Inc
NASDAQ:CING
Cingulate Inc
Total Current Liabilities
Cingulate Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cingulate Inc
NASDAQ:CING
|
Total Current Liabilities
$5m
|
CAGR 3-Years
62%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Liabilities
$54.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Liabilities
$23.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Liabilities
$36.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Liabilities
$28.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Liabilities
$40.1B
|
CAGR 3-Years
33%
|
CAGR 5-Years
26%
|
CAGR 10-Years
17%
|
|
Cingulate Inc
Glance View
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form. Its CTx-1301 and CTx-1302 that are being developed for the treatment of ADHD, in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).
See Also
What is Cingulate Inc's Total Current Liabilities?
Total Current Liabilities
5m
USD
Based on the financial report for Dec 31, 2024, Cingulate Inc's Total Current Liabilities amounts to 5m USD.
What is Cingulate Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
11%
Over the last year, the Total Current Liabilities growth was -51%. The average annual Total Current Liabilities growth rates for Cingulate Inc have been 62% over the past three years , 11% over the past five years .
